Alteration of TP53 functions is a well-known negative prognostic factor for MDS and AML patients treated with conventional chemotherapy [10, 13] and allogeneic stem cell transplantation [14–16], which has justified investigation of alternative TP53-independent therapy such as HMA. The gene discussed is TP53; the disease is acute myeloid leukemia.